Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Background The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved
for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have …

Brain metastases signify a deleterious milestone in the progression of several advanced
cancers, predominantly originating from lung, breast and melanoma malignancies, with a …

Excessive inflammation caused by abnormal activation of the NLRP3 inflammasome
contributes to the pathogenesis of multiple human diseases, but clinical drugs targeting the …

Although comprehensive biomarker testing is recommended for all patients with
advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line …

Background Advancements in the field of precision medicine have prompted the European
Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the …

Introduction Select tyrosine kinase inhibitors (TKIs) used to treat oncogene-driven lung
cancers also inhibit MATE-1. When MATE-1 is blocked, creatinine is retained in the serum …

Acquired drug resistance remains a major problem across oncogene-addicted cancers.
Elucidation of mechanisms of resistance can inform rational treatment strategies for patients …

Objectives NTRK fusions result in constitutively active oncogenic TRK proteins responsible
for∼ 0.2% of non-small cell lung cancer (NSCLC) cases. Approximately 40% of patients with …

Background ROS1 fusion-positive (ROS1+) nonsmall cell lung cancer (NSCLC) patients are
highly sensitive to tyrosine kinase inhibitor (TKI) treatments. However, acquired TKI …